GINS2 was shown to be associated with the progression of several cancers, including lung cancer [14, 15], breast cancer [16], cervical cancer [17], leukemia [18], and thyroid cancer [19], by manipulating several signaling pathways, such as the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin (mTOR) [20], P53/growth arrest and DNA damage-inducible protein 45 alpha [14], and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways [15]. This evidence concerns the gene MTOR and thyroid gland carcinoma.